JENNIFER GILL
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health PHILADELPHIA, PA NPI 1558784124
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health PA Daiichi Sankyo Inc. All categories
General Payments — all program years on this page
$2,219.20
- Category: General Payments
- Program years: PY2021–2024
- Record count: 88
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,526.88 across 69 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,447.88 | 68 |
| Education | $79.00 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $207.85 | 20 |
| SHIELD THERAPEUTICS INC | $164.84 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $124.14 | 5 |
| GlaxoSmithKline, LLC. | $122.09 | 1 |
| Janssen Biotech, Inc. | $107.70 | 4 |
| Merck Sharp & Dohme Corporation | $85.65 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $70.63 | 3 |
| Incyte Corporation | $68.36 | 3 |
| Acerta Pharma LLC | $67.51 | 3 |
| Alexion Pharmaceuticals, Inc. | $52.15 | 2 |
| EISAI INC. | $50.99 | 2 |
| ABBVIE INC. | $47.94 | 3 |
| TOLMAR, INC. | $38.34 | 2 |
| Genmab U.S., Inc. | $27.36 | 1 |
| Rigel Pharmaceuticals, Inc. | $26.98 | 1 |
| Pharmacosmos Therapeutics Inc. | $24.96 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $24.91 | 1 |
| TerSera Therapeutics LLC | $23.61 | 1 |
| BeiGene USA, Inc. | $23.61 | 1 |
| Apellis Pharmaceuticals, Inc. | $23.41 | 1 |
| Tempus AI, Inc | $23.08 | 1 |
| Fennec Pharmaceuticals, Inc. | $21.64 | 1 |
| Genentech USA, Inc. | $21.48 | 1 |
| PharmaEssentia USA Corporation | $21.33 | 1 |
| Sumitomo Pharma America, Inc. | $19.64 | 1 |
| Celgene Corporation | $19.17 | 1 |
| Janssen Pharmaceuticals, Inc | $17.51 | 1 |
By program year
Records — PY2024 (69)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.